Mobility in Atypical Parkinsonism: a Trial of Physiotherapy
Mobility in Atypical Parkinsonism: a Trial of Physiotherapy
Patients with atypical parkinsonism often show gait and mobility impairment manifesting in
 early disease stages.

 In order to maintain mobility and physical autonomy as long as possible for these patients,
 we will examine the effect of two types of physiotherapy in patients with multiple system
 atrophy (MSA), progressive supranuclear gaze palsy (PSP) and idiopathic Parkinson's disease
 (IPD).

 The study is divided into an ambulant daily in-patient physiotherapy phase, followed by a
 home-based training phase. At the beginning and the end of the study, the patients daily
 activity will be recorded for one week using Physical Activity Monitoring (PAM) sensors.

 The aim of this double-blind, randomized-controlled study is to determine effective
 physiotherapy in patients with atypical parkinsonian syndromes in order to maintain mobility
 for as long as possible.
Patients with Parkinson's disease often show gait impairment and reduced mobility over the
 disease course. Rare atypical forms of parkinsonism, like multiple system atrophy (MSA) or
 progressive supranuclear gaze palsy (PSP) develop these features in early disease stages. The
 reduced mobility and increased time spent in sitting or lying posture leads to loss of
 physical independence and increased mortality. Since MSA and PSP can currently only be
 treated symptomatically, a long lasting independence and mobility is therefore of great
 importance.

 A positive effect has already been shown in a few studies on specific physiotherapy in
 patients with idiopathic Parkinson's disease (IPD), and some small studies also give us an
 evidence that physiotherapy in atypical parkinsonism can improve mobility.

 The Mobility_APP study examines the effect of two types of physiotherapy in patients with
 MSA, PSP and IPD. The participants are initially assigned to a type of therapy and they learn
 specific exercises with a physiotherapist every day for two weeks. These exercises will then
 be continued independently at home for another five weeks. Regular checks in the study center
 ensure a precise examination of the physical condition, quality of life and gait pattern. The
 latter will be objectively analyzed with the help of sensors that are worn on the
 participant's shoes. In addition, before the start and at the end of the study, the
 participants are also monitored for one week at home using shoe sensors in order to reflect
 the natural conditions of the patients.

 During the entire study, neither the participant nor the study investigator knows what type
 of therapy is being used in order to guarantee an unbiased analysis (double blinding).

 The aim of this double-blind, randomized-controlled study is to determine effective
 physiotherapy in patients with atypical parkinsonian syndromes in order to maintain mobility
 for as long as possible. If the exercises learned during physiotherapy can be continued
 regularly at home and can improve mobility, this means a big step towards autonomous therapy.
 Frequent visits to therapists can be reduced and sufficient and effective independent therapy
 can still be carried out during times of crisis or phases with increased motor impairment.

 The project is kindly supported by the Fund for the Promotion of Scientific Research (FWF).
 Together with the German Research Foundation (DFG) and Swiss National Science Foundation
 (SNF) in Switzerland this project can be carried out internationally in cooperation with
 renowned centers for neurological and sensor-based research.
Inclusion Criteria:

 -  The subject is willing and able to give written informed consent

 -  The patient is able to tolerate all study visits including daily physiotherapy and
 home training.

 -  Patients similar with regard to age and sex with probable/possible MSA-P according to
 rev. Gilman criteria OR probable/possible PSP-RS according to MDS-PSP criteria OR PD
 according to MDS-PD criteria.

 -  Stable antiparkinsonian and Anti-OH medication 4 weeks prior to study entry.

 Exclusion Criteria:

 -  Co-morbidities that influence the clinical presentation of parkinsonian symptoms (as
 judged by the enrolling investigator).

 -  Participation in other clinical trials that might influence the impact of the trial
 intervention (as judged by the enrolling investigator)

 -  H&Y Staging score greater than or equal to 4

 -  Change of antiparkinsonian and anti-OH medication 4 weeks prior to the interventional
 trial.

 -  Secondary cause of autonomic failure or parkinsonism (e.g. diabetic autonomic
 neuropathy, bladder surgery, drug-induced or vascular parkinsonism, etc.)

 -  Dementia according to DSM-V.